###begin article-title 0
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
A single amino acid determines preference between phospholipids and reveals length restriction for activation ofthe S1P4 receptor
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 636 638 636 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Sphingosine-1-phosphate and lysophosphatidic acid (LPA) are ligands for two related families of G protein-coupled receptors, the S1P and LPA receptors, respectively. The lysophospholipid ligands of these receptors are structurally similar, however recognition of these lipids by these receptors is highly selective. A single residue present within the third transmembrane domain (TM) of S1P receptors is thought to determine ligand selectivity; replacement of the naturally occurring glutamic acid with glutamine (present at this position in the LPA receptors) has previously been shown to be sufficient to change the specificity of S1P1 from S1P to 18:1 LPA.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 640 642 636 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
We tested whether mutation of this "ligand selectivity" residue to glutamine could confer LPA-responsiveness to the related S1P receptor, S1P4. This mutation severely affected the response of S1P4 to S1P in a [35S]GTPgammaS binding assay, and imparted sensitivity to LPA species in the order 14:0 LPA > 16:0 LPA > 18:1 LPA. These results indicate a length restriction for activation of this receptor and demonstrate the utility of using LPA-responsive S1P receptor mutants to probe binding pocket length using readily available LPA species. Computational modelling of the interactions between these ligands and both wild type and mutant S1P4 receptors showed excellent agreement with experimental data, therefore confirming the fundamental role of this residue in ligand recognition by S1P receptors.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 391 393 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Glutamic acid in the third transmembrane domain of the S1P receptors is a general selectivity switch regulating response to S1P over the closely related phospholipids, LPA. Mutation of this residue to glutamine confers LPA responsiveness with preference for short-chain species. The preference for short-chain LPA species indicates a length restriction different from the closely related S1P1 receptor.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 550 560 550 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2/3/4/5 </sub>
###xml 622 628 622 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2/3 </sub>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1279 1281 1279 1281 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1288 1290 1288 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1342 1343 1342 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1344 1345 1344 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1530 1532 1530 1532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1610 1612 1610 1612 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1657 1658 1657 1658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are phospholipid growth factors which are present in normal serum and plasma. These lipids elicit diverse responses from a wide range of cell types, including enhanced cell survival, cell proliferation, induction of cytoskeletal changes and chemotaxis (reviewed in [1-4]. Some of these responses reflect activation of G protein-coupled receptors of the endothelial differentiation gene (Edg) family. The Edg receptor family is classified into two clusters based on ligand selectivity: S1P1/2/3/4/5 (formerly Edg1/5/3/6/8) specifically respond to S1P whilst LPA1/2/3 (formerly Edg2/4/7) respond to LPA [5]. Members of the S1P receptor family display higher sequence similarity to each other (approximately 40% identity) than to members of the LPA receptor family (approximately 30% identity). These homologies, coupled with observed differences in the structure of S1P and LPA receptor genes, suggest that these receptor families evolved from distinct ancestral genes. The S1P receptors contain a conserved glutamic acid residue present within the third TM that corresponds to glutamine in the LPA receptors. Interaction between distinct functional groups present on S1P and LPA with this residue was shown for the S1P1 and LPA1 receptors using computational modelling techniques [6,7] and was demonstrated as the basis for the ligand preference displayed by the receptors. Experimental characterisation confirmed that replacement of glutamic acid with glutamine in S1P1 changed ligand specificity from S1P to LPA, and the reciprocal mutation in LPA1 resulted in recognition of both LPA and S1P [7].
###end p 9
###begin p 10
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 188 190 188 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 286 288 286 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 579 588 579 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 644 646 644 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 782 791 782 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 803 805 803 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 883 885 883 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1002 1004 998 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1053 1055 1045 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 1057 1060 1049 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 1368 1370 1360 1362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1501 1503 1493 1495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
In the present study, the role of this residue in determining ligand selectivity for the S1P4 receptor was examined. Phylogenetic analysis of the Edg family of receptors indicates that S1P4 is more closely related to other S1P receptors than receptors which respond to LPA. However, S1P4 lies on the edge of the S1P family cluster and has been shown to bind S1P with lower affinity than other S1P receptors and hence it has been suggested that S1P is not the true endogenous agonist of this receptor [8]. We therefore decided to investigate whether replacement of this residue (E3.29(122)) with glutamine conferred LPA-responsiveness to the S1P4 receptor and hence determine the role of this residue in this lower-affinity S1P receptor. To achieve this, we expressed wild type and E3.29(122)Q mutant S1P4 receptors in CHO-K1 cells and studied responses to lysophospholipids using a [35S]GTPgammaS binding assay. Since CHO-K1 cells respond to LPA, we utilised fusion proteins constructed between the S1P4 receptor and a pertussis toxin-insensitive Galphai1(C351I) G protein. Expression of these proteins in CHO-K1 cells followed by treatment with pertussis toxin prior to harvest allowed elimination of any signal due to stimulation of endogenous LPA receptors. Within this study, we also examined how the length of the LPA acyl chain affected potency at the mutant S1P4 receptor, using a panel of naturally occurring LPA analogues. Computational models of complexes between the wild type or mutant S1P4 receptor and S1P and LPA species were used to provide a molecular interpretation of the experimental findings.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
###xml 12 14 12 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 254 256 250 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 258 261 254 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 359 360 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 367 369 359 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 371 374 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 387 388 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 390 399 382 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 408 410 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 412 415 400 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 577 579 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 584 586 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 824 825 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human HA-S1P4 was mutated at position 122 to replace the naturally occurring glutamic acid with glutamine. The mutant and wild type receptors were stably expressed in CHO-K1 cells as in-frame GPCR-G protein fusions with pertussis toxin-insensitive Galphai1(C351I). Western blotting was used to detect expression of these fusion proteins. Membranes from HA-S1P4-Galphai1(C351I)- or HA-S1P4(E3.29(122)Q)-Galphai1(C351I)-transfected cells contained a polypeptide with an apparent molecular mass of approximately 110 kDa, which reacted with anti-HA and anti-SG1 antibodies (Figure 1A and 1B) and was consistent with expression of the GPCR-G protein fusion. Confirmation of comparable cell-surface expression of these proteins was obtained via FACS analysis using an anti-HA antibody directly conjugated with fluorescein (Figure 1 Panel III).
###end p 12
###begin p 13
###xml 20 21 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 28 31 24 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 41 42 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 44 47 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">122</sup>
###xml 56 58 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 60 63 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 0 83 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of HA-S1P<sub>4</sub>-G&#945;<sub>i1 </sub>and HA-S1P<sub>4</sub>(E<sup>122</sup>Q)-G&#945;<sub>i1</sub>(C<sup>351</sup>I) in CHO-K1 cells. </bold>
###xml 175 176 167 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 183 185 171 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 187 190 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 206 207 194 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 209 212 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">122</sup>
###xml 221 223 205 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 225 228 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 307 310 287 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 521 523 501 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 593 595 573 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
Expression of HA-S1P4-Galphai1 and HA-S1P4(E122Q)-Galphai1(C351I) in CHO-K1 cells. Membranes from untransfected CHO-K1 cells (lane 2) and CHO-K1 cells stably expressing HA-S1P4-Galphai1(C351I) (A) or HA-S1P4(E122Q)-Galphai1(C351I) (B) were analysed by Western blotting using anti-HA (panel I) or anti-Galphai1 (panel II) antibodies. Visualisation of immunoreactive proteins was achieved using chemiluminescence after incubation of the blot with appropriate HRP-conjugated secondary antibodies. The position of each HA-S1P4 fusion protein is indicated by an arrow. Cell-surface expressed HA-S1P4 receptor was detected by FACS analysis (panel III) using a Fluorescein conjugate of the anti-HA antibody (blue line). Cells were also stained with an isotype matched control antibody (red line). No staining of untransfected CHO-K1 cells was observed using the Fluorescein conjugate of the anti-HA antibody (not shown). Data are presented as overlay histograms and are representative of at least five independent experiments.
###end p 13
###begin p 14
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 30 32 26 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 34 37 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 50 51 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 53 62 49 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 71 73 63 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 75 78 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 258 260 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 310 311 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 318 320 302 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 322 325 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 338 341 322 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 405 406 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 408 417 390 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 426 428 404 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 430 433 408 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 508 510 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 519 522 497 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 555 556 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 563 566 537 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 687 689 659 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 722 724 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 853 854 823 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 868 870 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The response of HA-S1P4-Galphai1(C351I) and HA-S1P4(E3.29(122)Q)-Galphai1(C351I) to S1P was assessed using membranes from cells transfected to express these proteins and treated with pertussis toxin prior to harvest. S1P promoted dose-dependent increase in [35S]GTPgammaS binding to membranes containing HA-S1P4-Galphai1(C351I) with an EC50 of 355 nM +/- 155 nM (n = 3); in contrast, membranes from HA-S1P4(E3.29(122)Q)-Galphai1(C351I)-expressing cells demonstrated severely impaired response to S1P (Figure 2A). The EC50 for S1P stimulation of the HA-S1P4-Galphai1 fusion protein (355 +/- 155 nM) was not statistically significantly different from that obtained using the unfused HA-S1P4 receptor (439 +/- 187 nM, Figure 2B) and compared favourably with published values for this receptor in HEK293T cells from two different research groups of 270 nM [9] and 790 nM [10].
###end p 14
###begin p 15
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 29 31 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 33 36 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 49 50 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 52 61 48 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 70 72 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 74 77 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 91 93 83 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 0 120 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sensitivity of HA-S1P<sub>4</sub>-G&#945;<sub>i1</sub>(C<sup>351</sup>I) and HA-S1P<sub>4</sub>(E<sup>3.29(122)</sup>Q)-G&#945;<sub>i1</sub>(C<sup>351</sup>I) to S1P in [<sup>35</sup>S]GTP&#947;S binding assay. </bold>
###xml 174 175 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 182 184 166 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 186 189 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 193 207 177 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled squares</italic>
###xml 218 219 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 221 230 205 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 239 241 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 243 246 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 250 262 230 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 451 453 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 486 488 452 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 769 771 733 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 772 786 736 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled squares</italic>
###xml 798 799 762 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 806 809 766 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 825 841 785 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled triangles</italic>
###xml 973 976 933 936 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
Sensitivity of HA-S1P4-Galphai1(C351I) and HA-S1P4(E3.29(122)Q)-Galphai1(C351I) to S1P in [35S]GTPgammaS binding assay. A. Membranes from CHO-K1 cells transfected with HA-S1P4-Galphai1(C351I) (filled squares) or HA-S1P4(E3.29(122)Q)-Galphai1(C351I) (open circles) which had been cultured in the presence of 100 ng/mL pertussis toxin for 24 hours prior to harvest were stimulated with varying concentrations of S1P for 30 minutes at 30degreesC in the [35S]GTPgammaS binding assay. Galphai G proteins were immunoprecipitated after solubilisation and preclearance with non-immune serum. Data are the mean of three determinations +/- SEM from a single experiment, and are representative of three such experiments performed. B. Dose-dependent stimulation of wild-type HA-S1P4 (filled squares) and HA-S1P4-Galphai1 fusion protein (filled triangles) by S1P measured as described in panel A. These data are representative of three such experiments performed and analysis of mean EC50 values obtained for each protein showed them to be not statistically different.
###end p 15
###begin p 16
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 84 86 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 94 103 90 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 354 355 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 362 365 351 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 373 375 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 471 473 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 622 623 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 625 634 608 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 643 645 622 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 647 650 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 706 708 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 739 748 718 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 760 762 739 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 975 984 948 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 1311 1320 1282 1291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 1399 1401 1370 1372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
Structure activity relationships were determined by the [35S]GTPgammaS assay for S1P4 or its E3.29(122)Q mutant using S1P and LPA species with 14:0, 16:0 and 18:1 acyl chains at a single (10 muM) concentration. Of the lysophospholipids tested, only S1P induced a strong response over basal levels (approximately 48% +/- 5%) in membranes containing HA-S1P4-Galphai1 (Figure 3A), whilst 18:1 LPA did not stimulate a statistically significant response; weak stimulation of [35S]GTPgammaS binding was observed with 14:0 and 16:0 LPA (approximately 11% +/- 3% above basal in each case). In contrast, membranes containing HA-S1P4(E3.29(122)Q)-Galphai1(C351I) showed at least weak response to each ligand (Figure 3A). The weakest agonist at the E3.29(122)Q mutant S1P4 receptor was 18:1 LPA, which produced only 14% +/- 2% stimulation over basal. S1P and 16:0 LPA gave approximately 21% +/- 4% and 19% +/- 4% stimulation over basal response, respectively. The best agonist for the E3.29(122)Q mutant was 14:0 LPA, which gave a 40% +/- 2% enhancement over basal levels. The stimulation promoted by 14:0 LPA was statistically different from that produced by 18:1 LPA (p < 0.01). Sensitivity of the receptor to stimulation by each form of LPA, and particularly 14:0 LPA, was markedly increased after introduction of the E3.29(122)Q mutation and indicated that this position was important in influencing HA-S1P4 ligand preference.
###end p 16
###begin p 17
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">122</sup>
###xml 42 44 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 46 49 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 56 58 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 0 85 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ligand preference of HA-S1P<sub>4</sub>(E<sup>122</sup>Q)-G&#945;<sub>i1</sub>(C<sup>351</sup>I) in [<sup>35</sup>S]GTP&#947;S binding assay. </bold>
###xml 178 180 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 216 218 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 370 371 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 378 380 352 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 382 385 356 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 408 409 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 411 420 385 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 429 431 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 433 436 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 986 987 953 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 989 998 956 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 1007 1009 970 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 1011 1014 974 977 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 1101 1102 1064 1065 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1104 1107 1067 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink">122</sup>
###xml 1116 1118 1075 1077 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 1120 1123 1079 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 1254 1261 1213 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crosses</italic>
###xml 1274 1286 1233 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 1301 1317 1260 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled triangles</italic>
Ligand preference of HA-S1P4(E122Q)-Galphai1(C351I) in [35S]GTPgammaS binding assay. Membranes were stimulated for 30 minutes at 30degreesC with lysophospholipid ligands in the [35S]GTPgammaS binding assay and Galphai G proteins immunoprecipitated after solubilisation and preclearance with non-immune serum. (A) Membranes from CHO-K1 cells transfected to express HA-S1P4-Galphai1(C351I) or the mutant HA-S1P4(E3.29(122)Q)-Galphai1(C351I) and incubated with 100 ng/mL pertussis toxin for 24 hours prior to harvest, were left untreated (basal), or treated with vehicle or 10 muM concentrations of 18:1 LPA, 16:0 LPA, 14:0 LPA or S1P. Data are the mean of three determinations +/- SEM from a single experiment and are representative of three such experiments performed. Statistical significance from the basal responses of each set of membranes tested is denoted by * (P < 0.05) or ** (P < 0.01); ## denotes statistical significance from the response to 18:1 LPA (P < 0.01) for the HA-S1P4(E3.29(122)Q)-Galphai1(C351I)-transfected membranes. (B) Membranes from CHO-K1 cells transfected to express HA-S1P4(E122Q)-Galphai1(C351I) and incubated with 100 ng/mL pertussis toxin for 24 hours prior to harvest, were stimulated with various concentrations of S1P (crosses), 18:1 LPA (open circles) or 14:0 LPA (filled triangles). Data are the mean of three determinations +/- SEM and are representative of three such determinations performed.
###end p 17
###begin p 18
###xml 49 58 49 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 334 343 334 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 348 350 348 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 424 427 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 572 575 572 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 605 606 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 608 617 608 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 626 628 622 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 630 633 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 765 768 758 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 858 859 851 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 861 870 854 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 879 881 868 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 883 886 872 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 946 948 935 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
These results indicate that introduction of the E3.29(122)Q mutation in the S1P4 receptor confers LPA-responsiveness, and that a short form of LPA was a more effective agonist than the intermediate and longer forms, when tested at this single concentration. Dose response curves were constructed for ligand-induced activation of the E3.29(122)Q S1P4 mutant by the 14:0 and 18:1 forms of LPA as well as S1P (Figure 3B). An EC50 could only be determined for the 14:0 form of LPA as S1P and 18:1 LPA caused minimal stimulation at only the highest concentration tested. The EC50 value for activation of HA-S1P4(E3.29(122)Q)-Galphai1(C351I) was calculated to be 3.8 +/- 1.4 muM. However, since a plateau of maximal stimulation was not achieved, interpretation of this EC50 value needs caution. This result clearly showed that 14:0 LPA was a weak agonist of HA-S1P4(E3.29(122)Q)-Galphai1(C351I) and hence confirmed the involvement of residue 122 in S1P4 ligand preference. Similar results were obtained using a second CHO-K1 clone expressing this fusion protein (not shown).
###end p 18
###begin p 19
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 273 283 273 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.28(121) </sup>
###xml 288 297 288 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5.38(202)</sup>
###xml 371 380 371 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
Computational modelling of the S1P complex with the wild type S1P4 receptor identifies the best S1P binding site within the TM with the phosphate group at the extracellular end (Figure 4A). Ion pairs appear between the phosphate group of S1P and two cationic amino acids, R3.28(121) and K5.38(202). An additional ion pair occurs between the cationic ammonium of S1P and E3.29(122). Hydrophobic residues from TM2, TM3, TM5 and TM6 line the binding pocket and surround the alkyl chain of S1P.
###end p 19
###begin p 20
###xml 37 39 37 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Computational models of wild type S1P<sub>4 </sub>and its E3.29(122)Q mutant with S1P and LPA species. </bold>
###xml 155 157 155 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 165 174 165 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 738 740 738 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 886 888 886 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 923 932 923 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 937 939 937 939 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1215 1217 1215 1217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1292 1301 1292 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
Computational models of wild type S1P4 and its E3.29(122)Q mutant with S1P and LPA species. Computational models of the complexes between the wild type S1P4 or its E3.29(122)Q mutant with S1P or various LPA species generated by Autodock 3.0 and minimised using the MMFF94 forcefield in the MOE program. Complexes in each panel are shown from the same viewpoint with the extracellular end of the receptors oriented to the top of the figure. Standard element color codes are used with grey, white red, blue and magenta representing carbon, hydrogen, oxygen, nitrogen and phosphorous. Ribbons are shaded from red at the amino-terminus to blue at the carboxy-terminus. (A) Model of the complex between S1P (spacefilling) and the wild type S1P4 receptor. Residues in the receptor involved in ion pairs with S1P are shown as stick models and labelled. (B) Superimposition of the wild type S1P4 complex with S1P (orange) and the E3.29(122)Q S1P4 mutant complex with 14:0 LPA (green). For clarity, the only position at which the modelled amino acid position is shown for both receptor models is 3.29(122). Other residues had very similar optimised positions in the two model structures. (C) Superimposition of wild type S1P4 complexes with 18:1 LPA (cyan), 16:0 LPA (yellow) and 14:0 LPA (green) on E3.29(122)Q mutant complexes with 18:1 LPA (blue-green), 16:0 LPA (gold) and S1P (orange). For clarity, the only position at which modelled amino acid position is shown for both the wild type and mutant receptor models is 3.29(122). Other residues had very similar optimised positions in all model structures. (D) Space-filling models which represent the minimised extended conformation of each structure were constructed using SYBYL 6.9 software (Tripos Inc., St. Louis, MO., U.S.A.). The distance between phosphorus and terminal carbon atoms was predicted for each structure listed from top to bottom: 18:1 LPA, 27.0 A; 16:0 LPA, 26.7 A; 14:0 LPA, 24.2 A; S1P, 24.0 A.
###end p 20
###begin p 21
###xml 37 46 37 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 146 148 146 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 271 281 271 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.28(121) </sup>
###xml 286 295 286 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5.38(202)</sup>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
The best complex of 14:0 LPA in the E3.29(122)Q S1P4 mutant receptor model has striking similarity to the best complex of S1P in the wild type S1P4 receptor model (Figure 4B). Both models demonstrate ion pairing between the phosphate group and two cationic amino acids, R3.28(121) and K5.38(202). Each ligand interacts with the amino acid at position 3.29(122), S1P by an ion pair with the carboxylate of the wild type glutamate and 14:0 LPA by a hydrogen bond with the mutated glutamine. Multiple hydrophobic residues surround the nonpolar tails of the lipid ligands. The superimposition of the two complexes (Figure 4B) also demonstrates that the ligands occupy almost identical volumes. Common interactions and overlap volumes are qualitatively consistent with the experimental findings that these ligands give similar 48% and 40% maximal stimulation over basal for S1P at the wild type and 14:0 LPA at the mutant receptor, respectively.
###end p 21
###begin p 22
###xml 47 56 47 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 237 246 237 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 251 253 251 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 413 415 413 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 827 829 827 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 863 872 863 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 877 879 877 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1089 1091 1089 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1224 1226 1224 1226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1249 1258 1249 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 1263 1265 1263 1265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
In contrast to the complexes of 14:0 LPA with E3.29(122)Q S1P4 and S1P with wild type S1P4, the remaining complexes show much less common volume (Figure 4C). Most complexes exhibit the phosphate interactions described for 14:0 LPA with E3.29(122)Q S1P4 and S1P with wild type S1P4. Of particular interest is the observation that the best complexes generated by Autodock for the 18:1 LPA species with wild type S1P4 has a very high positive van der Waals interaction energy, > 3000 kcal/mol, compared to values well under 200 kcal/mol for every other complex studied. In the best complexes found for 16:0 LPA and 18:1 LPA in both constructs, the terminal six to eight carbons of the hydrophobic tails fold into L-shaped conformations quite different from the extended conformations observed in the S1P complex with wild type S1P4 or the 14:0 LPA complex with the E3.29(122)Q S1P4 mutant. The terminal carbons in several complexes curl out of the receptor between TM5 and TM6 (Figure 4C) due to the restricted length of the binding pocket. These results suggest that the complete lack of S1P4 activation in response to 18:1 LPA is likely due to failure to form a complex. The strongest complexes formed, S1P with wild type S1P4 and 14:0 LPA with the E3.29(122)Q S1P4 mutant, have complementary interactions with the residue at position 3.29(122). These strong complexes give the most robust activation. Weak complexes are formed for other combinations due to mismatched interactions with position 3.29(122) or excessive length of the hydrophobic tail. The presence of hydrophobic tails of 16:0 or 18:1 LPA between transmembrane domains may additionally impair the conformational change necessary for full agonist responses.
###end p 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 219 221 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 263 265 259 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 267 270 263 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 509 514 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 517 519 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 573 575 569 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Parental CHO-K1 cells respond to LPA in functional assays, reflecting expression of endogenous LPA1 (G. Holdsworth, et al., manuscript in preparation). For this reason, fusion proteins between wild type or mutant HA-S1P4 and the pertussis toxin-insensitive Galphai1(C351I) G protein were used in these studies. Expression of these proteins in CHO-K1 cells followed by treatment with pertussis toxin prior to harvest allowed elimination of any signal due to stimulation of endogenous LPA receptors. McAllister et al. [11] (.(adopted a similar approach for studies of the LPA1 receptor.
###end p 24
###begin p 25
###xml 33 43 33 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122) </sup>
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 253 255 253 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 290 299 290 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 347 349 347 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 552 554 552 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 627 628 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 630 639 630 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 652 655 652 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 738 740 737 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 791 800 790 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 805 807 804 806 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 833 835 832 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1319 1321 1318 1320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1322 1323 1321 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1324 1325 1323 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1334 1340 1333 1339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,2,3 </sub>
###xml 1341 1342 1340 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1343 1345 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
We examined the role of residue E3.29(122) in controlling S1P4 ligand selectivity using functional and computational methods. This residue, which is conserved throughout the S1P receptors, has been shown to control ligand specificity for the related S1P1 receptor [7]. Introduction of the E3.29(122)Q mutation severely affected the response of S1P4 to S1P: in dose-response experiments S1P caused minimal stimulation at only the highest concentration of ligand used. This is in agreement with published observations for activation of the equivalent S1P1 mutant [7]. 14:0 LPA was able to induce dose-dependent stimulation of S1P4(E3.29(122)Q) with an EC50 of approximately 3.8 muM but only promoted minimal stimulation of the wild type S1P4 receptor. The modelled complexes of 14:0 LPA with E3.29(122)Q S1P4 and S1P with wild type S1P4 demonstrate nearly identical volumes occupied by the two ligands and very similar interactions between these ligands and their respective receptors. Of particular importance are amino acid residues at positions 3.28(121), 3.29(122) and 5.38(202), which either ion pair with the phosphate or interact with the 2-amino or 2-hydroxyl group in S1P and 14:0 LPA, respectively. The importance of interactions with amino acids at positions 3.28 and 3.29 has been previously noted for the S1P1 [6,7] and LPA1,2,3 [7,12] receptors.
###end p 25
###begin p 26
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 138 147 138 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 379 380 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 495 497 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The S1P4 receptor exhibits marked constitutive (agonist-independent) activity (Figure 5) which was unaffected by the introduction of the E3.29(122)Q mutation (data not shown). This indicates that the mutation perturbs S1P recognition without affecting the ability of the receptor to spontaneously adopt an active conformation. Similar observations have been reported for the beta2AR, where a mutation in the sixth transmembrane domain abolished agonist activation but not constitutive activity [13].
###end p 26
###begin p 27
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 51 53 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 55 58 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 0 62 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Constitutive activity of HA-S1P<sub>4 </sub>and HA-S1P<sub>4</sub>-G&#945;<sub>i1</sub>(C<sup>351</sup>I). </bold>
###xml 204 206 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 215 217 206 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 248 250 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 363 364 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 538 539 525 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 546 549 529 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 827 828 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 835 837 814 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
Constitutive activity of HA-S1P4 and HA-S1P4-Galphai1(C351I). Comparison of basal, vehicle and stimulated (10 muM S1P) GTPgammaS binding for membranes prepared from CHO cells transfected to express HA-S1P4 or HA-S1P4 fused to PTx insensitive Galphai1. Where indicated, cells were treated with 100ng/ml PTx for 24 hours prior to harvesting. PTx treatment of HA-S1P4-transfected membranes prevented activation by S1P and also caused a dramatic reduction in basal signalling, indicative of constitutive activity. In contrast, when the HA-S1P4-Galphai1 fusion-expressing membranes were treated with PTx, there was only a slight reduction in basal signalling and the receptor still responded to exogenous S1P, indicating that the receptor signalled via the tethered, PTx-insensitive G protein. Basal signalling in PTx-treated HA-S1P4-Galphai1-expressing membranes exceeded that seen with membranes from untransfected CHO cells.
###end p 27
###begin p 28
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">o</italic>
###xml 154 156 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sn</italic>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 524 533 524 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 538 540 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1039 1041 1035 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1371 1372 1367 1368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1391 1395 1387 1391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;3 </sub>
###xml 1507 1509 1503 1505 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1516 1517 1512 1513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1579 1581 1575 1577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1588 1590 1584 1586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1625 1626 1621 1622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1741 1742 1737 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1770 1772 1766 1768 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1920 1922 1914 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Unlike S1P, which exists as a single species in vivo, the term LPA actually refers to a family of molecules that take the general form 1-o-acyl-2-hydroxy-sn-glyceryl-3-phosphate. Naturally occurring forms of LPA contain acyl chains of differing lengths, with differing degrees of saturation. Investigations into the effect of the length and degree of saturation of the acyl chain of LPA have been undertaken for the LPA receptors [14,15], but limited SAR information is available for S1P receptors (22). The LPA-responsive E3.29(122)Q S1P4 mutant facilitates structure activity relationship (SAR) studies due to the greater availability of LPA analogs relative to S1P analogs. Comparison of space-filling models of the structures of S1P and three analogues of LPA (Figure 4D) revealed that 14:0 LPA most closely resembled S1P in terms of apparent length. [35S]GTPgammaS binding assays demonstrated greater agonist activity of 14:0 LPA at the mutant receptor relative to 18:1 or 16:0 LPA. This SAR indicates a length restriction for the S1P4 agonist binding site. Model complexes of 16:0 and 18:1 LPA contained alkyl chains that fold at the bottom of the binding pocket, defined by a cluster of hydrophobic amino acids. Three of these differ either in position of sidechain branching or size relative to LPA receptors and the other S1P receptors. Position 2.46, I88 in S1P4, is leucine in LPA1-3 and other S1P receptors. Residue I6.40(256) is larger than the valine found in the other four S1P receptors, LPA1 and LPA3. Finally, I7.51(305) corresponds to the smaller valine in S1P2 and S1P3 and the much smaller alanine in LPA2. These findings provide a molecular explanation for a similar SAR observed using para-alkyl amide analogs of S1P [9]. SAR obtained with the S1P4 mutant are in contrast to that shown by LPA receptors, which exhibit the general trend of 18:1 >/= 16:0 > 14:0 for potency and maximal stimulation [15].
###end p 28
###begin p 29
###xml 40 42 40 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 429 430 429 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 519 520 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 561 571 561 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7.34(127) </sup>
###xml 576 586 576 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7.37(291) </sup>
###xml 591 601 591 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7.30(284) </sup>
###xml 632 642 632 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7.30(284) </sup>
###xml 1129 1131 1129 1131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1158 1163 1158 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Since mutation of residue 122 in the S1P4 receptor from the naturally occurring glutamic acid to glutamine conferred responsiveness to 14:0 LPA and severely affected responses to S1P, our observations support the hypothesis that this conserved residue in the third transmembrane domain of the S1P receptors is involved in ligand recognition. This is in contrast to a recent paper describing models of several GPCRs, including S1P4, which had been generated using novel first principle methods [16]. In this model of S1P4, interactions between S1P and residues T7.34(127) and W7.37(291) and E7.30(284) were observed. Interaction of E7.30(284) with the ammonium group of S1P appeared to control ligand selectivity since the other residues appeared to interact with the phosphate group, which is present on both LPA and S1P. It is therefore surprising that none of these residues are conserved throughout the S1P or LPA receptor families. The data presented here support the assertion that glutamic acid residue 3.29 present in the third transmembrane domain of the S1P receptors controls ligand selectivity and suggest that the S1P4 model described by Vaidehi et al. [16] is inaccurate.
###end p 29
###begin p 30
###xml 233 235 233 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 289 290 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 292 301 292 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(121)</sup>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 410 412 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The current study provides new information for the development of more selective S1P receptor agonists. In particular, an S1P analog with its hydrophobic chain extended by either 2 or 4 carbons would be a very poor agonist of the S1P4 receptor. On the other hand, the activation of the S1P1-E3.29(121)Q mutant by 18:1 LPA [7] indicates that a chain-extended S1P analog should retain agonist activity at the S1P1 receptor. S1P receptor agonists with differing selectivity profiles will be useful tools to more completely map the physiological and pathophysiological roles of these receptors.
###end p 30
###begin title 31
Conclusions
###end title 31
###begin p 32
###xml 360 362 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 511 513 511 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 569 571 569 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 635 637 635 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
These studies confirm that glutamic acid residue 3.29, present in the third transmembrane domain of the S1P receptors is important for the selective recognition of S1P, versus the closely related lipid, LPA. Mutation of E3.29 to glutamine diminished response to S1P and allowed structure activity studies using the diverse available LPA species. The mutant S1P4 receptor is stimulated most strongly by LPA 14:0 and is not activated by the longer LPA 18:1, in contrast with a previous report on the analogous S1P1 receptor mutant that responded to LPA 18:1. Thus the S1P4 receptor ligand binding pocket is shorter in length than the S1P1 ligand binding pocket.
###end p 32
###begin title 33
Methods
###end title 33
###begin title 34
Residue nomenclature
###end title 34
###begin p 35
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Amino acids within the TM of S1P4 can be assigned index positions to facilitate comparison between receptors with different numbers of amino acids, as described by Weinstein and coworkers [17]. An index position is in the format x.xx. The first number denotes the TM in which the residue appears. The second number indicates the position of that residue relative to the most highly conserved residue in that TM which is arbitrarily assigned position 50. E3.29, then, indicates the relative position of glutamate 122 in TM3 relative to the highly conserved arginine 143 in the E(D)RY motif which is assigned index position 3.50 [17].
###end p 35
###begin title 36
Materials
###end title 36
###begin p 37
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 96 102 <span type="species:ncbi:9913">bovine</span>
Materials for tissue culture were supplied by Invitrogen Ltd. (Paisley, Scotland, U.K.). Foetal bovine serum was obtained from Helena Biosciences Ltd., (Sunderland, U.K.) or PAA Labs GmbH., (Linz, Austria). Pertussis toxin was purchased from CN Biosciences Ltd., (Nottingham, U.K.). Lysophosphatidic acid (18:1, 16:0 and 14:0) and S1P were from Avanti Polar Lipids Inc., (Alabaster, AL., U.S.A.). The SG1 antiserum was produced previously [18]. All other chemicals were from Sigma Aldrich Company Ltd., (Gillingham, Dorset, U.K.) or BDH Ltd., (Poole, Dorset, U.K.) unless stated otherwise.
###end p 37
###begin title 38
Construction of receptor expression plasmids
###end title 38
###begin p 39
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 99 107 99 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GCGGCCGC</bold>
###xml 114 141 114 141 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TATCCATATGATGTTCCAGATTATGCT</underline>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 353 359 353 359 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GAATTC</bold>
###xml 359 362 359 362 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGC</underline>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 497 500 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 522 525 518 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 558 560 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 626 632 622 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GAATTC</bold>
###xml 682 685 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 755 761 751 757 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GGATCC</bold>
###xml 808 811 804 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1050 1052 1046 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1062 1064 1054 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 1066 1069 1058 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 43 48 <span type="species:ncbi:9606">human</span>
The S1P4 coding sequence was cloned from a human PBMC cDNA library using the sense primer 5'-GAGAGAGCGGCCGCCACCATGTATCCATATGATGTTCCAGATTATGCTAACGCCACGGGGACCCCGGTG-3', which contains a NotI restriction site (bold) and the haemagglutinin HA epitope tag (YPYDVPVYA, underlined) immediately after the initiator methionine, and the antisense primer 5'-GAGAGAGAATTCGGCGATGCTCCGCACGCTGGAGATG-3', which contains an EcoRI restriction site (bold) and changes the S1P4 stop codon to alanine (underlined). A C351I mutant of the Galphai1 G protein (previously produced, [19]) was amplified using PCR with the sense cloning primer 5'-GAGAGAGAATTCGCCA CCATGGGCTGCACACTGAGCG-3', which contains the EcoRI restriction site (bold), and the antisense cloning primer 5'-GAGAGAGGATCCTTAGAAGAGACCGATGTCTTTTA G-3', which contains a BamHI restriction site (bold). After digestion of each PCR product with the appropriate restriction enzymes, fragments were ligated into the pIRESpuro mammalian expression vector (Invitrogen Ltd.) to generate an in-frame fusion between HA-S1P4 and Galphai1(C351I).
###end p 39
###begin p 40
###xml 5 14 5 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 343 346 343 346 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CAG</underline>
###xml 411 414 411 414 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTG</underline>
###xml 575 577 575 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 843 846 839 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1 </sub>
###xml 935 936 931 932 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 938 947 934 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 960 962 952 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 964 967 956 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
The E3.29(122)Q mutation was introduced into the S1P4 sequence in parallel PCR reactions. Complementary oligonucleotides were designed across the residue which was to be mutated such that each primer contained the necessary base change to mutate residue 122 to glutamine (underlined in each primer): sense mutational primer: 5'-CAGTGGTTCCTACGGCAGGGCCTGCTCTTCAC-3'; antisense mutational primer: 5'-GTGAAGAGCAGGCCCTGCCGTAGGAACCACTG-3'. Mutational sense or antisense primers were used in parallel PCR reactions with the appropriate antisense or sense cloning primer, with HA-S1P4 plasmid DNA as template. Equimolar amounts of each purified PCR product were mixed and amplified in a further reaction, using the cloning primers described above. The resultant product was digested with the appropriate restriction enzymes and ligated with the Galphai1 sequence in the pIRESpuro expression vector to generate an in-frame fusion between HA-S1P4(E3.29(122)Q) and Galphai1(C351I).
###end p 40
###begin title 41
Cell culture and transfection
###end title 41
###begin p 42
###xml 53 55 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 276 277 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 284 286 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 288 291 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 303 304 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 306 315 296 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 324 326 310 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1</sub>
###xml 328 331 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">351</sup>
###xml 130 136 <span type="species:ncbi:9913">bovine</span>
CHO-K1 cells were maintained at 37degreesC with 5% CO2 in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine and non-essential amino acids. Sub-confluent cell monolayers were stably transfected to express either HA-S1P4-Galphai1(C351I) or HA-S1P4(E3.29(122)Q)-Galphai1(C351I) fusion proteins using Lipofectamine reagent (Invitrogen). 72 hours post-transfection, cells were seeded in media supplemented with 7.5 mug/mL puromycin and the resultant clones examined for expression of cell surface receptor using FACS analysis. Clonal cell lines were expanded in complete DMEM containing 7.5 mug/mL puromycin and were transferred to serum free DMEM approximately 24 hours prior to harvesting. Where indicated, 100 ng/mL pertussis toxin was included in the serum free medium.
###end p 42
###begin p 43
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 232 234 232 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 416 418 416 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
It should be noted that we initially expressed S1P4 in RH7777 cells, which are unresponsive to S1P and LPA and have been commonly used for studies of Edg family receptors [20]. Unfortunately, our attempts to detect activation of S1P4 expressed in these cells using a variety of functional assays were unsuccessful. Therefore, we used CHO-K1 cells as an alternative host in these studies; expression of functional S1P4 in CHO-K1 cells has also been reported by Mandala et al. [21].
###end p 43
###begin title 44
FACS analysis
###end title 44
###begin p 45
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The amino-terminal HA-epitope tag was detected using a fluorescein conjugate of the anti-HA antibody, clone 3F10 (Roche Molecular Biochemicals Ltd., Lewes, U.K.). Cells were harvested non-enzymatically and washed with FACS buffer (PBS containing 3% FBS and 0.1% NaN3) then stained with the 3F10 antibody (or an isotype matched control) for 40 minutes at 4degreesC in the dark. After washing with FACS buffer, cells were analysed using a FACScalibur flow cytometer (BD Biosciences, Oxon., U.K.).
###end p 45
###begin title 46
Preparation of cell membranes
###end title 46
###begin p 47
###xml 121 122 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 454 456 448 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
Cells were harvested non-enzymatically, washed with PBS and resuspended in "assay buffer" (20 mM Hepes, pH 7.4, 3 mM MgCl2, 100 mM NaCl), supplemented with "complete" protease inhibitors (Roche Molecular Biochemicals Ltd.). Cells were homogenised in a nitrogen cavitation chamber (500 psi for 15 minutes). Unbroken cells and nuclei were pelleted by centrifugation (500 x g, 10 minutes, 4degreesC) and the supernatant fraction was centrifuged at 45,000 x g for 45 minutes at 4degreesC. Membrane pellets were resuspended in assay buffer, titurated through a fine gauge needle and stored at -80degreesC until required.
###end p 47
###begin title 48
Immunoblot analysis
###end title 48
###begin p 49
###xml 380 388 380 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#945;i1 </sub>
###xml 327 330 <span type="species:ncbi:10116">rat</span>
###xml 509 520 <span type="species:ncbi:3704">horseradish</span>
Samples were resolved by SDS-Page on 4-20% Tris-Glycine gels (Invitrogen) and were transferred to Immobilon-P membrane (Millipore Ltd., Herts., U.K.). The membrane was blocked using 2.5% Marvel in PBS before incubating with primary antibodies which had been diluted in PBS/0.1% Tween-20 containing 1% Marvel. The high affinity rat anti-HA antibody was diluted 1 in 500; the anti-Galphai1 antibody (Autogen Bioclear Ltd., Wilts., U.K.) was diluted 1 in 1000. Immunoreactivity was detected using an appropriate horseradish peroxidase-conjugated secondary antibody, diluted 1 in 10,000 in PBS/0.1% Tween-20 containing 1% Marvel, followed by detection using SuperSignal reagents (Perbio Science Ltd., Cheshire, U.K.).
###end p 49
###begin title 50
###xml 1 3 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
[35S]GTPgammaS binding assay
###end title 50
###begin p 51
###xml 1 3 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 87 89 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 220 222 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 956 961 930 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i1/2 </sub>
[35S]GTPgammaS binding experiments were performed essentially as described previously [22]. Briefly, membranes were incubated with or without the indicated ligand for 30 minutes at 30degreesC in assay buffer containing [35S]GTPgammaS (100 nCi/point), saponin (20 mug/point) and 0.1 muM GDP. 18:1 LPA was prepared as a 2 mM DMSO stock whilst 16:0 and 14:0 LPA were prepared as 2 mM stock solutions in 1:1 ethanol:water per supplier recommendation due to their poor solubility in DMSO. S1P had previously been dispensed as thin film aliquots (dissolved in MeOH and the solvent evaporated under nitrogen) in brown glass vials and stored at -70degreesC prior to use. Lipids (S1P or LPA forms) were diluted in assay buffer containing 1% fatty acid free BSA, such that the final concentration of BSA in the assay was 0.1%. Following incubation, membrane protein was solubilised with 1.25% NP-40 and 0.4% SDS and after pre-clearance using non-immune serum, Galphai1/2 subunits were immunoprecipitated with SG1 antiserum, used at a dilution of 1 in 200. Non-specific binding was determined by the addition of 100 muM GTPgammaS. Bound radioactivity was measured using liquid scintillation counting.
###end p 51
###begin title 52
Experimental data analysis
###end title 52
###begin p 53
Numerical data are expressed as means +/- standard error, shown as error bars in the appropriate figures. Statistical comparisons were made using one-way ANOVA with Dunnett's multiple comparison post test.
###end p 53
###begin title 54
Receptor model development
###end title 54
###begin p 55
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 138 140 129 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 141 143 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 511 516 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 965 967 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 11 16 <span type="species:ncbi:9606">human</span>
A model of human S1P4 (GenBanktrade mark accession number AAP84350) was developed by homology to the experimentally-validated model of S1P1 [23]. Alignment of the S1P receptor sequences was performed using the MOE software package (version 2003. 01 ed. Chemical Computing Group, Montreal, Canada). The alignment was optimised by the manual removal of gaps within the TM, and alignment in the region of TM5 was shifted one position to correctly orient K5.38(202) toward the interior of the helical bundle (Pham, et al., unpublished data). A preliminary model was generated by homology modelling using default parameters and subsequently manually refined to optimise interhelical hydrogen bonding. Cis-amide bonds present in the loop regions were converted to the trans conformation by manual rotation followed by the minimisation of two residues on either side of the amide linkage to a root mean square (RMS) gradient of 0.1 kcal/mol.A using the MMFF94 forcefield [24]. After these manual refinements, the receptor model was optimised using the MMFF94 forcefield to an RMS gradient of 0.1 kcal/mol.A.
###end p 55
###begin p 56
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 26 35 26 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
A model of S1P4 with the E3.29(122)Q mutation was developed by performing the appropriate mutation in MOE, and saturating the residue with hydrogen atoms. To allow the sidechains of the other residues in the binding pocket to adapt to the presence of the new moiety, the backbone atoms of the receptor were fixed and the receptor was optimised to an RMS gradient of 0.1 kcal/mol.A using the MMFF94 forcefield [24].
###end p 56
###begin title 57
Ligand model development
###end title 57
###begin p 58
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Computational models of the naturally-occurring stereoisomers of 14:0 LPA, 16:0 LPA, 18:1 LPA, and S1P were built using the MOE software package. The -1 ionization state for the phosphate functionality was chosen for all ligands, and the +1 ionization state was chosen for the amine moiety of S1P. Previous docking studies using the -2 ionization state for phosphate in related systems yield essentially identical geometries as studies using the -1 ionization state. These ligands were geometry optimised using the MMFF94 force field [24].
###end p 58
###begin title 59
Docking
###end title 59
###begin p 60
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 108 110 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 127 129 127 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 130 139 130 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.29(122)</sup>
###xml 201 211 201 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3.33(126) </sup>
###xml 546 547 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Using the AUTODOCK 3.0 software package [25], 14:0 LPA, 16:0 LPA, 18:1 LPA, and S1P were docked into the S1P4 wild type and S1P4 E3.29(122)Q mutant receptor models. Each docking box was centered near F3.33(126) with dimensions of 30.75 x 23.25 x 23.25 or 32.25 x 23.25 x 23.25 A for shorter (S1P and 14:0 LPA) or longer (16:0 and 18:1 LPA) ligands, respectively. At least 20 putative complexes were generated for each receptor:ligand pair using docking parameters at default values with the exception of the number of energy evaluations (2.5 x 108), generations (10000) and maximum iterations (3000). Resultant complexes were evaluated based on final docked energy, Van der Waals interaction energies from the MMFF94 forcefield as well as visual analysis. The complexes with the lowest final docked energies and others of interest were geometry optimised using the MMFF94 force field [24], and the lowest energy complex after minimisation was chosen as the final complex structure.
###end p 60
###begin title 61
Abbreviations
###end title 61
###begin p 62
###xml 5 20 <span type="species:ncbi:10029">Chinese hamster</span>
CHO, Chinese hamster ovary; Edg, endothelial differentiation gene; ERK, extracellularly regulated kinase; FACS, fluorescence activated cell sorter; G protein, guanine nucleotide-binding protein; GPCR, G protein-coupled receptor; HA, haemagglutinin; LPA, lysophosphatidic acid; MAP, mitogen-activated protein kinase; PBMC, peripheral blood mononuclear cell; PTx, pertussis toxin; SIP, sphingosine-1-phosphate; TM, transmembrane domain
###end p 62
###begin title 63
Authors' contributions
###end title 63
###begin p 64
###xml 72 74 72 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 331 333 331 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 406 408 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 526 528 526 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 322 327 <span type="species:ncbi:9606">human</span>
G Holdsworth performed and interpreted all studies with experimental S1P4 fusion proteins and drafted the manuscript. D Osborne performed and interpreted docking studies to generate all mutant complexes with all LPA species and S1P and all wild type complexes with LPA species. TC Pham generated the homology model of the human S1P4 receptor. J Fells performed docking studies of S1P with the wild type S1P4 receptor. G Hutchinson and G Milligan participated in the design and coordination of the experimental studies with S1P4 fusion proteins. A Parrill participated in the design and coordination of the modelling studies and edited the manuscript.
###end p 64
###begin title 65
Acknowledgments
###end title 65
###begin p 66
We gratefully acknowledge the assistance of Jim Turner (Celltech R&D Ltd.) for production of lipid space-filling models and Gabor Tigyi (University of Tennessee Health Sciences Center) for critically reading the manuscript. This work was supported in part by grants from NIH (1 RO1 CA92160-01) and the American Heart Association (awards 0050006N and 0355199B). The Chemical Computing Group generously donated the MOE program.
###end p 66
###begin article-title 67
Sphingosine 1-phosphate Signalling and Termination at Lipid Phosphate Receptors
###end article-title 67
###begin article-title 68
Lysophospholipid Receptors
###end article-title 68
###begin article-title 69
Sphingosine-1-phosphate: An Enigmatic Signalling Lipid
###end article-title 69
###begin article-title 70
Signaling and Biological Actions of Sphingosine 1-phosphate
###end article-title 70
###begin article-title 71
International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature
###end article-title 71
###begin article-title 72
Structural Features of EDG1 Receptor-Ligand Complexes Revealed by Computational Modeling and Mutagenesis
###end article-title 72
###begin article-title 73
A Single Amino Acid Determines Ligand Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors
###end article-title 73
###begin article-title 74
Life on the Edg
###end article-title 74
###begin article-title 75
Synthesis of Para-Alkyl Aryl Amide Analogues of Sphingosine-1-phosphate: Discovery of Potent S1P Receptor Agonists
###end article-title 75
###begin article-title 76
The Immune modulator, FTY720, Targets Sphingosine 1-Phosphate Receptors
###end article-title 76
###begin article-title 77
Edg2 Receptor Functionality: Gialpha1 Coexpression and Fusion Protein Studies
###end article-title 77
###begin article-title 78
Molecular Basis for Lysophosphatidic Acid Receptor Antagonist Selectivity
###end article-title 78
###begin article-title 79
Mutation of Asn293 to Asp in Transmembrane Helix VI Abolishes Agonist-induced but not Constitutive Activity of the beta(2)-adrenergic Receptor
###end article-title 79
###begin article-title 80
###xml 50 55 <span type="species:ncbi:9606">Human</span>
Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid
###end article-title 80
###begin article-title 81
Molecular Cloning and Characterization of a Lysophosphatidic Acid Receptor, Edg-7, Expressed in Prostate
###end article-title 81
###begin article-title 82
Prediction of Structure and Function of G Protein-Coupled Receptors
###end article-title 82
###begin article-title 83
Chapter 19
###end article-title 83
###begin article-title 84
Differential G-protein Expression During B- and T-cell Development
###end article-title 84
###begin article-title 85
Hydrophobicity of Residue351 of the G Protein Gi1 alpha Determines the Extent of Activation by the Alpha 2A-Adrenoceptor
###end article-title 85
###begin article-title 86
###xml 30 36 <span type="species:ncbi:10090">Murine</span>
Comparative Analysis of Three Murine G-protein Coupled Receptors Activated by Sphingosine-1-phosphate
###end article-title 86
###begin article-title 87
Alteration of Lymphocyte Trafficking by Sphingosine 1-Phosphate Receptor Agonists
###end article-title 87
###begin article-title 88
Coordinated Agonist Regulation of Receptor and G Protein Palmitoylation and Functional Rescue of Palmitoylation-Deficient Mutants of the G Protein G11alpha Following Fusion to the Alpha1b-adrenoreceptor: Palmitoylation of G11alpha is not Required for Interaction with Beta*gamma Complex
###end article-title 88
###begin article-title 89
Identification of Edg1 Receptor Residues that Recognize Sphingosine 1- Phosphate
###end article-title 89
###begin article-title 90
Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94*
###end article-title 90
###begin article-title 91
Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function
###end article-title 91

